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Abstract
Introduction: A younger age at menarche and an older age at menopause are well established risk factors for
breast cancer. Recent genome-wide association studies have identified several novel genetic loci associated with
these two traits. However, the association between these loci and breast cancer risk is unknown.
Methods: In this study, we investigated 19 and 17 newly identified single nucleotide polymorphisms (SNPs) from
the ReproGen Consortium that have been associated with age at menarche and age at natural menopause,
respectively, and assessed their associations with breast cancer risk in 6 population-based studies among up to
3,683 breast cancer cases and 34,174 controls in white women of European ancestry. In addition, we used these
SNPs to calculate genetic risk scores (GRSs) based on their associations with each trait.
Results: After adjusting for age and potential population stratification, two age at menarche associated SNPs
(rs1079866 and rs7821178) and one age at natural menopause associated SNP (rs2517388) were associated with
breast cancer risk (p values, 0.003, 0.009 and 0.023, respectively). The odds ratios for breast cancer corresponding to
per-risk-allele were 1.14 (95% CI, 1.05 to 1.24), 1.08 (95% CI, 1.02 to 1.15) and 1.10 (95% CI, 1.01 to 1.20),
respectively, and were in the direction predicted by their associations with age at menarche or age at natural
menopause. These associations did not appear to be attenuated by further controlling for self-reported age at
menarche, age at natural menopause, or known breast cancer susceptibility loci. Although we did not observe a
statistically significant association between any GRS for reproductive aging and breast cancer risk, the 4th and 5th
highest quintiles of the younger age at menarche GRS had odds ratios of 1.14 (95% CI, 1.01 to 1.28) and 1.13 (95%
CI, 1.00 to 1.27), respectively, compared to the lowest quintile.
Conclusions: Our study suggests that three genetic variants, independent of their associations with age at
menarche or age at natural menopause, were associated with breast cancer risk and may contribute modestly to
breast cancer risk prediction; however, the combination of the 19 age at menarche or the 17 age at natural
menopause associated SNPs did not appear to be useful for identifying a high risk subgroup for breast cancer.
Introduction
A younger age at menarche and an older age at meno-
pause are well-established risk factors for the develop-
ment of breast cancer [1]. In the general population, the
risk of breast cancer decreases by 10% for each 2-year
delay in menarche [2] but increases by 3% for each year
that menopause is delayed [3]. These associations are
consistent with the hypothesis that breast cancer risk is
related to the extent of steroid hormone exposure dur-
ing a woman’s reproductive years, which drives breast
mitotic activity and determines the probability of
tumorigenic somatic events [4].
Recently, genome-wide association studies (GWAS)
have identified several new common genetic loci
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associated with either age at menarche or age at natural
menopause. Four independent GWAS of age at
menarche have identified two novel loci at LIN28B and
9q31.2 [5-8], and two GWAS of age at natural meno-
pause have identified four novel loci on chromosomes 5,
6, 19, and 20 [5,9]. Most recently, the ReproGen Con-
sortium, which consisted of these initial GWASs and
many additional studies, has conducted expanded meta-
analyses for age at menarche [10] and age at natural
menopause [11] and reported more new loci identified
for each trait. Given the well-established associations of
age at menarche and age at natural menopause with
breast cancer risk, we set out to assess whether these
common genetic loci influence breast cancer risk and
whether a genetic risk score (GRS) for these reproduc-
tive events might be useful for identifying a high-risk
subgroup for breast cancer. Furthermore, since the
reproductive risk factors have been observed to be dif-
ferentially associated with breast cancer by tumor histo-
logical subtypes [12-16], we assessed these genetic
associations by tumor histological subtypes defined by
estrogen receptor (ER) status.
We therefore conducted a meta-analysis of six popula-
tion-based studies to investigate the association between
genetic loci associated with age at menarche or age at
natural menopause and breast cancer risk. We assessed
19 and 17 single-nucleotide polymorphisms (SNPs) that
have been previously reported to be linked to age at
menarche [10] and age at natural menopause [11],
respectively, among up to 3,683 breast cancer cases and
34,174 controls in women of European ancestry and
evaluated whether these SNPs were differentially asso-
ciated with breast cancer subtypes defined by ER status
in two studies in which such data were available.
Materials and methods
Study population
The ReproGen Consortium was formed by more than
30 studies in the US and Europe to investigate the
genetics of reproductive aging traits [10,11]. Our
analysis used data from six population-based studies
from the ReproGen Consortium: the Nurses’ Health
Study (NHS), the Women’s Genome Health Study
(WGHS), the SardiNIA Breast Cancer Study (SardiNIA),
the Rotterdam Study I and II (RSI+II), the Framingham
Heart Study (FHS), and the Atherosclerosis Risk in
Communities Study (ARIC). Each study had at least 200
breast cancer cases. Four studies were prospective
cohort studies, one was a nested case-control study, and
one was a case-control study. A description of the six
studies is provided in Table 1, and more information is
given in Additional file 1. Briefly, breast cancer cases
occurring in defined populations during specific periods
of time were identified by structured questionnaires,
medical records, or linkage with a nationwide registry of
cancer or death index or both. By the time we con-
ducted this study, the majority of the women in these
studies had passed through menopause. As most of the
participants in these studies were European whites, we
restricted analyses to women of European ancestry. We
excluded subjects with missing information on age. Two
studies (NHS and WGHS) provided information on the
ER status of the breast tumors for a subset of the cases.
This information was extracted from medical records.
Each study was approved by the relevant local institu-
tional review boards.
Genotype data
We analyzed genotypes for 19 and 17 independent SNPs
with reported associations with age at menarche and age
at natural menopause, respectively, in the ReproGen
Consortium, in which all SNPs achieved genome-wide
significance in the meta-analysis of each trait (combined
stage 1 and replication P value of less than 1 × 10-8)
[10,11]. None of these SNPs has been reported to be
associated with breast cancer risk in previous GWAS
and this is likely because of the very stringent P value
threshold used to declare genome-wide significance
(usually, P values were less than at least 1 × 10-7). As
positive controls, 10 SNPs with consistently reported
Table 1 List of participating studies and number of case and control subjects
Study
acronym
Study name Study design Case
subjects
(n = 3,683)
ER+/ER-
subjects
(n = 1,716/371)
Control
subjects
(n = 34,174)
All subjects
(n =
37,857)
NHS-BC Nurses’ Health Study-Breast Cancer Nested case-
control
1,145 (31.1) 807/181 1,142 (3.3) 2,287 (6.0)
WGHS Women’s Genome Health Study Prospective cohort 1,099 (29.8) 909/190 22,205 (65.0) 23,304 (61.5)
SardBC SardiNIA Breast Cancer Study Case-control 809 (22.0) - 674 (2.0) 1,483 (3.9)
RSI+II Rotterdam Study I and II Prospective cohort 216 (5.9) - 4,261 (12.5) 4,477 (11.8)
FHS Framingham Heart Study Prospective cohort 207 (5.6) - 3,698 (10.8) 3,905 (10.3)
ARIC Atherosclerosis Risk in Communities
Study
Prospective cohort 207 (5.6) - 2,194 (6.4) 2,401 (6.3)
Data are presented as the number (percentage) of cases, controls, and all subjects. ER, estrogen receptor.
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associations with breast cancer as shown in recent
GWAS were included [17-19]. All 46 SNPs are listed in
Table S1 of Additional file 2. Genotypes used in this
analysis have been previously described [10,11]. Com-
plete genotype data from a total of up to 3,683 cases
and 34,174 control subjects were available for analysis
after the exclusions described in the ‘Study population’
section.
Breast cancer risk factors
The six studies from the ReproGen Consortium pro-
vided information on one or more of the following risk
factors for breast cancer: age (continuous, at study entry
or diagnosis), age at menarche (continuous, between 9
and 17 years), age at natural menopause (continuous,
between 40 and 60 years), age at first live birth (less
than 20, 20 to 24, 25 to 29 or no birth, at least 30
years), family history of breast cancer in first-degree
relatives (yes/no), alcohol consumption (less than 5, 5 to
15, 15 to 30, at least 30 g/day), parity (0, 1 to 2, at least
3), menopausal hormone therapy (ever/never), oral con-
traceptive (OC) use (ever/never), and adult body mass
index (BMI) (continuous).
Genetic risk score computation
The GRS was calculated on the basis of the 19 and 17
independent SNPs identified in previous studies as being
associated with age at menarche and age at natural
menopause, respectively [10,11]. As a younger age at
menarche and an older age at menopause are indepen-
dently associated with an elevated breast cancer risk, we
computed separate GRSs for a younger age at menarche
and an older age at natural menopause. The risk allele
was defined as an allele that was associated with a
younger age at menarche or an older age at natural
menopause. Two methods were used to determine the
GRS: a simple count method (count GRS) and a
weighted method (weighted GRS). We assumed an addi-
tive genetic model for each SNP, applying a linear
weighting of 0, 1, or 2 to genotypes containing 0, 1, or 2
risk alleles, respectively. The count method assumes that
each SNP contributes equally to the risk of breast can-
cer. The count GRS was calculated by simply summing
the number of risk alleles of each SNP. For the weighted
GRS, each SNP was weighted by b-coefficients obtained
from the replication studies of recent meta-analyses of
two traits [10,11]. The weighted GRS was calculated by
multiplying each b-coefficient by the number of corre-
sponding risk alleles (0, 1, or 2) and then summing the
products. To simplify interpretation and facilitate com-
parison with the count GRS, the weighted GRS was
further divided by twice the sum of the b-coefficients
and then multiplied by the total number of risk alleles.
To provide a positive control and also to control for
potential confounding by known breast cancer-asso-
ciated genetic variants, a count GRS was computed on
the basis of the 10 SNPs with consistently reported asso-
ciations with breast cancer [19]: rs2981582, rs3803662,
rs11249433, rs7716600, rs13387042, rs889312,
rs13281615, rs999737, rs3817198, and rs1045485.
Statistical analysis
In each of the six studies, we performed logistic regres-
sion to evaluate the association with breast cancer for
each of the 46 candidate SNPs, assuming an additive
genetic model. Logistic regression was also used to ana-
lyze the association between GRS and breast cancer by
including both GRSs for age at menarche and age at
natural menopause in the model as the main effects.
The GRSs were modeled as continuous variables or
categorized into quintiles, and the cutoff points for
quintiles were based on the WGHS population, which is
the largest prospective cohort population among all par-
ticipating studies. This approach was applied to each of
the six participating studies. Odds ratios (ORs) and 95%
confidence intervals (CIs) were estimated from logistic
regression. To control for potential confounding by
population stratification, we adjusted for the top princi-
pal components of genetic variation chosen for each
study. We adjusted for age in the main model. To
examine whether the genetic association of each of the
candidate SNPs or GRSs with breast cancer is mediated
through the onset of menarche or natural menopause,
we then adjusted for self-reported age at menarche and
age at natural menopause in the main model. Other
conventional risk factors for breast cancer - including
age at first live birth, family history of breast cancer in
first-degree relatives, alcohol consumption, parity,
menopausal hormone therapy, OC use, and adult BMI -
were further included in the model to control for poten-
tial confounding in studies which had such data avail-
able. To examine whether these genetic associations
differ by breast cancer subtypes, in each of the two stu-
dies that provided information on ER status, we then
investigated the genetic association of each of the candi-
date SNPs or GRSs with breast cancer in subgroup ana-
lysis by ER histological status (positive or negative).
Forest plots were used to present study-specific ORs
and 95% CIs. We then performed meta-analyses by
using the fixed-effects model to estimate summary ORs
from study-specific estimatesthat were weighted by the
inverse of the variance of each study. As the meta-ana-
lyses restricted to prospective cohort studies or case-
control studies yielded similar results, we present results
from only the meta-analysis of all six participating stu-
dies. We also tested the heterogeneity of associations
across studies as well as across different tumor subtypes
by using the Q test [20].
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All statistical analyses were performed by using SAS
version 9.1 software (SAS Institute Inc., Cary, NC,
USA). Power calculations were carried out by using
Quanto (University of Southern California, Los Angeles,
CA, USA). All P values were based on two-sided tests
and were considered statistically significant if less than
0.05. Because SNPs were selected on the basis of an a
priori hypothesis, adjustments for multiple comparison
tests were not performed.
Results
The six participating studies contributed 3,683 breast
cancer cases and 34,174 controls of self-reported white
women of European ancestry (Table 1), all with available
data on age and the 46 candidate SNPs, and at least one
of the conventional risk factors considered. Of the 3,683
cases, about 52% were from the four prospective cohort
studies (WGHS, RSI+II, FHS, and ARIC), about 30%
were from the nested case-control study in NHS, and
about 18% were from the population-based case-control
study in SardiNIA. ER status was known for 2,087 cases
in the NHS and the WGHS. On average, compared with
the controls, the cases had a younger age at menarche
and an older age at natural menopause. The expected
associations with breast cancer were generally observed
for the conventional risk factors across all of the studies
(Table S2 of Additional file 3). The associations of the
46 candidate SNPs with age at menarche or age at nat-
ural menopause in the six studies were consistent with
the original findings from the two meta-analyses [10,11].
Table 2 shows the risk allele frequency and the corre-
sponding per-risk-allele OR of breast cancer for each of
the 46 candidate SNPs. The results are arranged in
order of the strength of statistical significance (P value).
The allele frequency for each SNP in the controls was
similar to those reported for populations of European
descent [21-23]. After adjusting for age and potential
population stratification, we found that, among the 19
candidate SNPs for a younger age at menarche, two
SNPs, rs1079866 and rs7821178, were significantly asso-
ciated with breast cancer risk and had corresponding
per-risk-allele ORs of 1.14 (96% CI = 1.05 to 1.24; P
value = 0.003; P for heterogeneity = 0.37) and 1.08 (95%
CI = 1.02 to 1.15; P value = 0.009; P for heterogeneity =
0.43), respectively. The SNP rs1079866 is located about
250 kb away from the INHBA gene on chromosome 7,
whereas SNP rs7821178 is about 181 kb away from the
PXMP3 gene (also known as PEX3) on chromosome 8.
The strongest GWAS hit for age at menarche,
rs7759938 at LIN28B on chromosome 6, was not found
to be associated with breast cancer risk (P value = 0.60).
Of the 17 candidate SNPs associated with an older age
at natural menopause, one SNP, rs2517388, was signifi-
cantly associated with breast cancer risk with a per-risk-
allele OR of 1.10 (95% CI = 1.01 to 1.20; P value =
0.023; P for heterogeneity = 0.08). This SNP is an intro-
nic SNP in the ASH2L gene on chromosome 8. The
study-specific and summary ORs for the three associated
SNPs are shown in Figure 1. Further adjustment for
conventional risk factors - including age at menarche,
age at natural menopause, age at first live birth, family
history of breast cancer in first-degree relatives, alcohol
consumption, parity, menopausal hormone therapy, OC
use, and adult BMI - did not change the results substan-
tially. For candidate loci for age at menarche and age at
natural menopause, the findings did not differ materially
when we further adjusted for known breast cancer-asso-
ciated SNPs.
To evaluate the combined effect of candidate SNPs on
breast cancer risk, we calculated a GRS for each trait by
using either a count GRS or a weighted GRS approach.
The mean values of count and weighted GRSs were
20.41 and 20.03, respectively, for age at menarche and
16.21 and 14.32, respectively, for age at natural meno-
pause (Table 3). Based on the count GRS for a younger
age at menarche, the OR for breast cancer associated
with each point scored, corresponding to 1 risk allele,
was 1.01 (95% CI = 1.00 to 1.03) after age and potential
population stratification were adjusted for. ORs did not
increase linearly across quintiles of GRS for age at
menarche (P for trend = 0.06). Compared with women
in the lowest quintile, women in the fourth and fifth
quintiles had ORs for breast cancer of 1.14 (95% CI =
1.01 to 1.28) and 1.13 (95% CI = 1.00 to 1.27), respec-
tively. Results were similar when analyses were per-
formed by using weighted GRS. Overall, we did not
observe statistically significant associations between
breast cancer risk and age at natural menopause when
either count or weighted GRS was used.
In secondary analyses, we then determined whether
the associations of the 46 candidate SNPs with breast
cancer vary across tumor subtypes defined by ER status
in the NHS and the WGHS (Table 4). For the two SNPs
(rs1079866 and rs7821178) that had reported associa-
tions with age at menarche and that were associated
with overall breast cancer risk, we found no statistically
significant evidence that the associations differed across
subtypes (P for heterogeneity = 0.31 and 0.66, respec-
tively), although rs1079866 appeared to have a stronger
association with ER+ tumors (per-allele OR = 1.26; 95%
CI = 1.12 to 1.41) than with ER- tumors (per-allele OR
= 1.11; 95% CI = 0.89 to 1.38). Of note, one SNP that
had a reported association with age at menarche,
rs17188434, had a significantly stronger association with
ER- tumors (per-allele OR = 1.51; 95% CI = 1.15 to
1.98) than with ER+ tumors (per-allele OR = 1.08; 95%
CI = 0.92 to 1.26; P for heterogeneity = 0.035). Another
SNP that had a reported association with age at
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Table 2 Association of candidate single-nucleotide polymorphism loci and the risk of breast cancer
SNP Gene(s)a Distance
from gene
Chromosome Position
(Build 36)
Risk/Reference
allelesb
Effect
allele
Allele frequencyc of
cases/controlsd
Effect SE OR (95%
CI)e
P
valuef
Directiong P value for
heterogeneityh
Age at menarche
rs1079866 INHBA ~250 kb 7 41436618 C/G c 0.87/0.85 0.132 0.044 1.14
(1.05-1.24)
0.003 ++–+- 0.37
rs7821178 PXMP3 ~181 kb 8 78256392 A/C a 0.35/0.33 0.081 0.031 1.08
(1.02-1.15)
0.009 ++–++ 0.43
rs7642134 VGLL3 ~70 kb 3 86999572 A/G a 0.39/0.38 0.058 0.03 1.06
(1.00-1.12)
0.056 ++++-+ 0.83
rs10980926 ZNF483 Intronic 9 113333455 G/A g 0.64/0.65 -0.057 0.031 0.94
(0.89-1.00)
0.066 —+– 0.58
rs1398217 FUSSEL18 Intronic 18 43006236 G/C g 0.42/0.42 0.048 0.03 1.05
(0.99-1.11)
0.10 ++-+++ 0.40
rs17188434 NR4A2 ~84 kb 2 156805022 C/T c 0.07/0.07 0.075 0.059 1.08
(0.96-1.21)
0.20 +++— 0.34
rs13187289 PHF15 ~12 kb 5 133877076 C/G c 0.80/0.80 -0.038 0.038 0.96
(0.89-1.04)
0.32 —+-+ 0.03
rs12617311 PLCL1 ~195 kb 2 199340810 A/G a 0.32/0.32 -0.032 0.033 0.97
(0.91-1.03)
0.33 –+-+- 0.81
rs17268785 CCDC85A Intronic 2 56445587 A/G a 0.84/0.84 0.037 0.041 1.04
(0.96-1.12)
0.37 -+-+++ 0.89
rs2002675 TRA2B,
ETV5
~4 kb, ~135
kb
3 187112262 A/G a 0.58/0.57 0.022 0.03 1.02
(0.96-1.08)
0.47 ++++– 0.92
rs466639 RXRG Intronic 1 163661506 T/C t 0.12/0.12 -0.032 0.046 0.97
(0.89-1.06)
0.49 -+-+– 0.35
rs1659127 MKL2 ~28 kb 16 14295806 G/A g 0.67/0.66 0.022 0.033 1.02
(0.96-1.09)
0.50 +++++- 0.28
rs9635759 CA10 ~94 kb 17 46968784 G/A g 0.69/0.70 -0.021 0.034 0.98
(0.92-1.05)
0.54 -+–+- 0.32
rs10899489 GAB2 Intronic 11 77773021 C/A c 0.85/0.84 0.025 0.041 1.03
(0.95-1.11)
0.54 ++++– 0.97
rs10423674 CRTC1 Intronic 19 18678903 C/A c 0.67/0.67 0.017 0.032 1.02
(0.96-1.08)
0.59 +++-+- 0.60
rs7759938 LIN28B ~26 kb 6 105485647 T/C t 0.69/0.69 -0.017 0.032 0.98
(0.92-1.05)
0.60 +-+— 0.53
rs2090409 TMEM38B ~400 kb 9 108006909 A/C a 0.33/0.33 0.012 0.031 1.01
(0.95-1.08)
0.69 –++-+ 0.21
rs6438424 3q13.32 Intergenic 3 119057512 A/C a 0.50/0.50 0.002 0.029 1.00
(0.95-1.06)
0.94 —+++ 0.88
rs6589964 BSX ~18 kb 11 122375893 A/C a 0.48/0.48 -0.001 0.031 1.00
(0.94-1.06)
0.99 –++++ 0.20
Age at natural menopause
rs2517388 ASH2L Intronic 8 38096889 G/T g 0.17/0.16 0.096 0.042 1.10
(1.01-1.20)
0.023 +++-+- 0.08
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Table 2 Association of candidate single-nucleotide polymorphism loci and the risk of breast cancer (Continued)
rs4693089 HEL308 Intronic 4 84592646 G/A g 0.47/0.48 -0.06 0.031 0.94
(0.89-1.00)
0.054 ———— 0.38
rs11668344 TMEM150B Intronic 19 60525476 A/G a 0.64/0.64 -0.049 0.03 0.95
(0.90-1.01)
0.11 +——— 0.02
rs2307449 POLG Intronic 15 87664932 T/G t 0.60/0.61 -0.045 0.031 0.96
(0.90-1.02)
0.15 -+–+- 0.20
rs16991615 MCM8 Missense 20 5896227 A/G a 0.07/0.06 0.079 0.06 1.08
(0.96-1.22)
0.18 +++–+ 0.80
rs12294104 C11orf46,
PPED2
~24 kb,~49 kb 11 30339475 T/C t 0.17/0.17 0.046 0.039 1.05
(0.97-1.13)
0.24 ++-++- 0.56
rs12461110 NLRP11 Missense 19 61012475 G/A g 0.64/0.65 -0.036 0.031 0.96
(0.91-1.03)
0.24 –++-+ 0.32
rs2303369 FNDC4 Intronic 2 27568920 C/T c 0.62/0.63 -0.031 0.03 0.97
(0.91-1.03)
0.31 –++-+ 0.22
rs4886238 TDRD3 Intronic 13 60011740 A/G a 0.35/0.34 0.029 0.031 1.03
(0.97-1.09)
0.35 ++—— 0.79
rs2277339 PRIM1 Missense 12 55432336 T/G t 0.90/0.89 0.037 0.05 1.04
(0.94-1.14)
0.46 ++++– 0.47
rs10852344 GSPT1,
TNFRSF17
~7 kb, ~42 kb 16 11924420 C/T c 0.41/0.41 0.020 0.030 1.02
(0.96-1.08)
0.50 ++–++ 0.87
rs10183486 TLK1 Intronic 2 171699217 C/T c 0.62/0.62 -0.015 0.031 0.99
(0.93-1.05)
0.63 –+–+ 0.98
rs4246511 RHBDL2 Intronic 1 39152972 T/C t 0.27/0.27 0.016 0.035 1.02
(0.95-1.09)
0.66 ++—+ 0.69
rs2153157 SYCP2L Intronic 6 11005474 A/G a 0.50/0.50 0.011 0.029 1.01
(0.96-1.07)
0.70 ++-+-+ 0.59
rs1635501 EXO1 Intronic 1 240107398 T/C t 0.53/0.52 0.011 0.034 1.01
(0.95-1.08)
0.74 +-+–+ 0.31
rs365132 UIMC1 Synonymous 5 176311180 T/G t 0.50/0.50 -0.009 0.03 0.99
(0.93-1.05)
0.76 +-+–+ 0.58
rs1046089 BAT2 Missense 6 31710946 G/A g 0.65/0.65 -0.008 0.031 0.99
(0.93-1.05)
0.79 -+-+-+ 0.24
Breast cancer
rs2981582 FGFR2 Intronic 10 123342307 A/G a 0.44/0.38 0.188 0.03 1.21
(1.14-1.28)
4.7 ×
10-10
++++++ 0.10
rs3803662 TOX3 ~6 kb 16 51143842 A/G a 0.31/0.25 0.166 0.032 1.18
(1.11-1.26)
2.6 ×
10-7
++++-+ 0.31
rs11249433 FCGR1B ~245 kb 1 120982136 G/A g 0.44/0.46 0.149 0.031 1.16
(1.09-1.23)
1.9 ×
10-6
+++++- 0.26
rs7716600 MRPS30 ~59 kb 5 44910762 A/C a 0.24/0.20 0.148 0.035 1.16
(1.08-1.24)
2.3 ×
10-5
++++++ 0.80
rs13387042 TNP1 ~181 kb 2 217614077 A/G a 0.55/0.50 0.114 0.029 1.12
(1.06-1.19)
1.0 ×
10-4
++-+++ 0.20
rs889312 MAP3K1 ~43 kb 5 56067641 C/A c 0.30/0.32 0.122 0.032 1.13
(1.06-1.20)
1.5 ×
10-4
++++++ 0.65
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Table 2 Association of candidate single-nucleotide polymorphism loci and the risk of breast cancer (Continued)
rs13281615 8q24.21 Intergenic 8 128424800 G/A g 0.43/0.50 0.107 0.03 1.11
(1.05-1.18)
3.0 ×
10-4
++++– 0.01
rs999737 RAD51L1 Intronic 14 68104435 C/T c 0.77/0.80 0.079 0.035 1.08
(1.01-1.16)
0.024 ++++-+ 0.31
rs3817198 LSP1 Intronic 11 1865582 C/T c 0.32/0.34 0.049 0.032 1.05
(0.99-1.12)
0.13 +++-++ 0.45
rs1045485 CASP8 Missense 2 201857834 G/C g 0.88/0.92 0.067 0.045 1.07
(0.98-1.17)
0.13 ++–++ 0.75
aNearest gene(s); bthe risk allele refers to the allele associated with a younger age at menarche, an older age at natural menopause, or an increased risk of breast cancer; ceffect allele frequency; deffect allele
frequency in case or control subjects, respectively; eper effect allele change in log odds ratio (OR) of breast cancer; fP value from meta-analysis with additive genetic coding after adjustment for age and top genetic
principle components; gdirection of effect allele association with breast cancer in the six studies in order: Nurses’ Health Study, Women’s Genome Health Study, SardiNIA Breast Cancer Study, Rotterdam Study I and
II, Framingham Heart Study, and Atherosclerosis Risk in Communities Study; hP value from heterogeneity test across studies with 5 degrees of freedom. CI, confidence interval; SE, standard error; SNP, single-
nucleotide polymorphism.
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Figure 1 Forest plots for the three candidate loci (rs1079866, rs7821178, and rs2517388) in association with breast cancer risk. Per-
risk-allele odds ratios (ORs) and 95% confidence intervals (CIs) were obtained from unconditional logistic regression in each study, and age and
potential population stratification were adjusted for. The size of the box is inversely proportional to the standard error of the log OR estimate. P
values for heterogeneity across studies are 0.37, 0.43, and 0.08, respectively. ARIC, Atherosclerosis Risk in Communities Study; FHS, Framingham
Heart Study; NHS, Nurses’ Health Study; RSI+II, Rotterdam Study I, II; SardiNIA, SardiNIA Breast Cancer Study; WGHS, Women’s Genome Health
Study.
Table 3 Association between genetic risk score and risk of breast cancer
Quintile of GRS
Continuous
GRS
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for
trend
Count GRSa
Age at menarche
Cases/Controls 3,683/34,174 677/6,694 739/6,814 731/6,788 783/6,915 753/6,963
Mean/Median GRS
(range)b
20.41 (9.12-
31.95)
17.00 (9.12-
18.09)
19.02 (18.09-
19.86)
20.37 (19.86-
21.05)
21.90 (21.05-
22.74)
23.89 (22.74-
31.95)
OR (95% CI)c 1.01 (1.00-1.03) 1.00 1.10 (0.97-1.24) 1.01 (0.89-1.14) 1.14 (1.01-1.28) 1.13 (1.00-1.27) 0.06
Age at natural menopause
Cases/Controls 3,683/34,174 740/6,699 751/6,948 719/6,787 755/6,929 718/6,811
Mean/Median GRS
(range)b
16.21 (4.15-
26.52)
12.95 (4.15-
14.01)
14.91 (14.01-
15.62)
16.15 (15.62-
16.90)
17.64 (16.90-
18.37)
19.55 (18.37-
26.52)
OR (95% CI)c 1.00 (0.98-1.01) 1.00 1.02 (0.90-1.15) 0.93 (0.82-1.05) 1.02 (0.90-1.14) 0.98 (0.87-1.11) 0.54
Breast cancer
Cases/Controls 3,683/34,174 537/6,864 542/6,525 660/6,716 956/7,352 988/6,717
Mean/Median GRS
(range)b
8.88 (1.06-
16.96)
6.04 (1.06-7.01) 7.99 (7.01-8.05) 8.99 (8.05-9.07) 9.99 (9.07-10.86) 11.31 (10.86-
16.96)
OR (95% CI)c 1.13 (1.11-1.15) 1.00 1.19 (1.04-1.37) 1.38 (1.21-1.57) 1.60 (1.41-1.81) 1.89 (1.67-2.14) 1.5 × 10-31
Weighted GRSa
Age at menarche
Cases/Controls 3,683/34,174 762/8,961 711/6,811 752/6,287 728/6,059 736/6,056
Mean/Median GRS
(range)b
20.03 (7.15-
32.17)
16.12(7.15-
17.50)
18.47 (17.50-
19.31)
20.07 (19.31-
20.83)
21.63 (20.83-
22.55)
23.82 (22.55-
32.17)
OR (95% CI)c 1.01 (1.00-1.03) 1.00 1.02 (0.90-1.15) 0.99 (0.88-1.13) 1.02 (0.90-1.16) 1.11 (0.98-1.26) 0.12
Age at natural menopause
Cases/Controls 3,683/34,174 749/7,038 728/6,915 756/6,749 696/6,668 755/6,804
Mean/Median GRS
(range)b
14.32 (2.78-
26.21)
11.13 (2.78-
12.18)
12.96 (12.18-
13.61)
14.24 (13.61-
14.88)
15.57 (14.88-
16.39)
17.63 (16.39-
26.21)
OR (95% CI)c 1.00 (0.98-1.01) 1.00 1.07 (0.95-1.20) 0.97 (0.86-1.09) 1.00 (0.88-1.13) 1.03 (0.91-1.16) 0.73
aSee the ‘Materials and methods’ section for count genetic risk score (GRS) and weighted GRS computation; bmean for continuous GRS and median for each
quintile; cadjusted for age and potential population stratification. CI, confidence interval; OR, odds ratio.
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Table 4 Association of candidate single-nucleotide polymorphism loci and risk of breast cancer by estrogen receptor
status in the Nurses’ Health Study and Women’s Genome Health Study
SNP All cases ER+ ER- ER+/ER-
OR (95% CI)a P valueb OR (95% CI)a P valueb OR (95% CI)a P valueb P value for heterogeneityc
Cases/Controlsd 2,087/23,319 1,716/23,319 371/23,319
Age at menarche
rs1079866 1.22 (1.10-1.35) 2.0 × 10-4 1.26 (1.12-1.41) 7.3 × 10-5 1.11 (0.89-1.38) 0.34 0.31
rs7821178 1.12 (1.04-1.20) 3.3 × 10-3 1.10 (1.01-1.19) 0.025 1.14 (0.98-1.34) 0.10 0.66
rs17188434 1.15 (1.00-1.33) 0.048 1.08 (0.92-1.26) 0.34 1.51 (1.15-1.98) 2.7 × 10-3 0.035
rs13187289 0.92 (0.84-1.00) 0.055 0.90 (0.82-0.99) 0.026 1.05 (0.87-1.28) 0.60 0.15
rs10980926 0.93 (0.87-1.00) 0.067 0.94 (0.87-1.02) 0.14 0.90 (0.77-1.05) 0.17 0.58
rs7642134 1.06 (0.99-1.14) 0.12 1.07 (0.99-1.16) 0.089 1.09 (0.93-1.27) 0.28 0.86
rs10423674 1.05 (0.97-1.13) 0.22 1.06 (0.97-1.15) 0.19 0.95 (0.81-1.11) 0.50 0.23
rs6589964 0.95 (0.89-1.03) 0.22 0.94 (0.87-1.02) 0.13 1.00 (0.85-1.17) 0.98 0.51
rs1398217 1.04 (0.97-1.12) 0.25 1.02 (0.95-1.10) 0.57 1.11 (0.95-1.29) 0.19 0.36
rs1659127 1.03 (0.96-1.12) 0.41 1.00 (0.92-1.09) 0.98 1.09 (0.92-1.29) 0.32 0.38
rs12617311 0.97 (0.89-1.05) 0.44 1.00 (0.91-1.09) 0.93 0.94 (0.79-1.12) 0.48 0.56
rs17268785 1.04 (0.94-1.14) 0.48 1.07 (0.96-1.19) 0.22 0.83 (0.68-1.00) 0.055 0.023
rs2090409 0.97 (0.90-1.05) 0.50 0.96 (0.89-1.05) 0.38 0.98 (0.84-1.15) 0.82 0.85
rs10899489 1.03 (0.93-1.14) 0.52 1.02 (0.92-1.14) 0.67 0.98 (0.79-1.21) 0.86 0.72
rs6438424 0.98 (0.91-1.05) 0.55 0.99 (0.92-1.07) 0.79 0.98 (0.84-1.14) 0.76 0.88
rs2002675 1.02 (0.95-1.10) 0.55 1.04 (0.96-1.12) 0.35 0.94 (0.81-1.10) 0.45 0.27
rs466639 1.02 (0.92-1.14) 0.73 1.05 (0.94-1.18) 0.39 0.94 (0.74-1.20) 0.62 0.41
rs7759938 1.01 (0.93-1.09) 0.84 1.02 (0.94-1.11) 0.63 1.00 (0.84-1.17) 0.96 0.80
rs9635759 1.01 (0.93-1.09) 0.88 1.00 (0.92-1.09) 0.98 1.03 (0.87-1.22) 0.72 0.74
Age at natural menopause
rs2517388 1.14 (1.03-1.25) 0.010 1.11 (1.00-1.24) 0.046 1.32 (1.09-1.61) 4.7 × 10-3 0.12
rs2303369 0.93 (0.86-1.00) 0.036 0.93 (0.86-1.01) 0.076 0.94 (0.80-1.09) 0.42 0.94
rs12461110 0.93 (0.86-1.00) 0.042 0.91 (0.84-0.99) 0.022 0.95 (0.81-1.11) 0.50 0.66
rs4886238 1.06 (0.99-1.14) 0.11 1.06 (0.98-1.15) 0.14 1.03 (0.88-1.21) 0.68 0.76
rs16991615 1.09 (0.94-1.26) 0.23 1.13 (0.97-1.32) 0.12 0.99 (0.71-1.37) 0.94 0.46
rs2277339 1.07 (0.95-1.20) 0.28 1.09 (0.96-1.24) 0.21 1.02 (0.80-1.31) 0.85 0.68
rs12294104 1.04 (0.95-1.14) 0.41 1.06 (0.96-1.17) 0.28 0.98 (0.80-1.21) 0.89 0.54
rs4246511 1.03 (0.95-1.12) 0.42 1.05 (0.96-1.15) 0.29 0.95 (0.79-1.14) 0.59 0.34
rs10852344 1.03 (0.96-1.10) 0.42 1.04 (0.96-1.12) 0.31 0.99 (0.85-1.15) 0.88 0.56
rs2153157 1.03 (0.96-1.10) 0.45 1.04 (0.96-1.12) 0.32 1.00 (0.87-1.17) 0.95 0.69
rs4693089 0.98 (0.91-1.05) 0.54 0.98 (0.91-1.07) 0.68 0.91 (0.77-1.06) 0.23 0.37
rs10183486 0.98 (0.91-1.06) 0.67 0.98 (0.91-1.06) 0.64 0.91 (0.78-1.06) 0.23 0.39
rs2307449 0.99 (0.92-1.06) 0.72 0.96 (0.89-1.04) 0.36 1.06 (0.91-1.24) 0.47 0.29
rs1635501 0.99 (0.91-1.07) 0.76 0.99 (0.90-1.08) 0.80 0.99 (0.83-1.19) 0.94 0.97
rs11668344 1.01 (0.94-1.08) 0.81 1.00 (0.92-1.08) 0.92 1.05 (0.89-1.22) 0.58 0.59
rs1046089 0.99 (0.92-1.07) 0.89 1.02 (0.94-1.10) 0.67 0.90 (0.77-1.05) 0.19 0.17
rs365132 1.00 (0.93-1.07) 0.97 1.00 (0.93-1.08) 1.00 1.00 (0.86-1.16) 0.95 0.96
Breast cancer
rs11249433 1.20 (1.12-1.29) 4.8 × 10-7 1.23 (1.14-1.33) 6.9 × 10-8 1.06 (0.91-1.23) 0.45 0.081
rs3803662 1.20 (1.12-1.30) 1.8 × 10-6 1.26 (1.16-1.37) 4.2 × 10-8 0.98 (0.82-1.16) 0.78 0.008
rs2981582 1.18 (1.10-1.27) 8.2 × 10-6 1.19 (1.10-1.29) 1.1 × 10-5 1.01 (0.87-1.19) 0.86 0.071
rs13281615 1.16 (1.08-1.24) 3.9 × 10-5 1.16 (1.07-1.25) 2.1 × 10-4 1.15 (0.99-1.33) 0.074 0.94
rs13387042 1.15 (1.07-1.23) 8.4 × 10-5 1.17 (1.08-1.26) 6.3 × 10-5 1.01 (0.87-1.18) 0.85 0.10
rs7716600 1.17 (1.08-1.27) 1.6 × 10-4 1.18 (1.08-1.29) 2.9 × 10-4 1.21 (1.02-1.44) 0.029 0.77
rs889312 1.10 (1.02-1.19) 0.012 1.10 (1.01-1.20) 0.026 1.18 (1.00-1.39) 0.046 0.45
rs999737 1.09 (1.00-1.18) 0.049 1.10 (1.01-1.21) 0.031 0.99 (0.84-1.18) 0.95 0.29
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menarche, rs17268785, was associated with a decreased
risk of ER- tumors (per-allele OR = 0.83; 95% CI = 0.68
to 1.00) but an increased risk of ER+ tumors (per-allele
OR = 1.07; 95% CI = 0.96 to 1.19; P for heterogeneity =
0.023). For the SNP that had a reported association with
age at natural menopause and that was associated with
overall breast cancer risk, we observed a stronger asso-
ciation with ER- tumors (per-allele OR = 1.32; 95% CI =
1.09 to 1.61) than ER+ tumors (per-allele OR = 1.11;
95% CI = 1.00 to 1.24); however, the test for heteroge-
neity was not statistically significant (P for heterogeneity
= 0.12). When the count GRS for age at menarche or
age at natural menopause was applied to ER+ and ER-
breast cancer separately, the trend in the OR for ER+
tumors was very similar to that for overall breast cancer.
The ER- tumor data suggested a somewhat different pat-
tern, although the statistical power was limited for this
subtype (Figure 2).
Of the 10 candidate SNPs with consistently reported
associations with breast cancer risk, five SNPs
(rs11249433, rs3803662, rs2981582, rs13387042, and
rs999737) appeared to have a stronger association with
ER+ tumor than ER- tumors, and rs3803662 reached sta-
tistical significance (P for heterogeneity = 0.008) with
per-risk-allele ORs of 1.26 (95% CI = 1.16 to 1.37) and
0.98 (95% CI = 0.82 to 1.16) for ER+ and ER- tumors,
Table 4 Association of candidate single-nucleotide polymorphism loci and risk of breast cancer by estrogen receptor
status in the Nurses?’? Health Study and Women?’?s Genome Health Study (Continued)
rs1045485 1.09 (0.98-1.20) 0.12 1.06 (0.95-1.19) 0.28 1.20 (0.95-1.52) 0.12 0.35
rs3817198 1.03 (0.96-1.12) 0.38 1.06 (0.98-1.15) 0.16 0.88 (0.74-1.04) 0.13 0.047
aPer-risk-allele odds ratio (OR) of breast cancer; bP value from meta-analysis of the Nurses’ Health Study (NHS) and the Women’s Genome Health Study (WGHS)
with additive genetic coding after adjustment for age and potential population stratification; cP value from heterogeneity test across estrogen receptor-positive
(ER+) and ER- tumors; dtotal number of cases or controls in the NHS and the WGHS. CI, confidence interval; SNP, single-nucleotide polymorphism.
Figure 2 The associations between groups defined by quintiles of genetic risk scores (GRSs) and risk of breast cancer by estrogen
receptor (ER) status in the Nurses’ Health Study and the Women’s Genome Health Study. (a) Count GRS for age at menarche. (b) Count
GRS for age at natural menopause. (c) Count GRS for breast cancer-associated SNPs. CI, confidence interval.
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respectively (Table 4). Two breast cancer candidate
SNPs, rs1045485 and rs3817198, did not show statisti-
cally significant associations with overall risk. However,
rs1045485 appeared to have a stronger association with
ER- tumors (per-allele OR = 1.20; 95% CI = 0.95 to
1.52) than ER+ tumors (per-allele OR = 1.06; 95% CI =
0.95 to 1.19; P for heterogeneity = 0.35), and rs3817198
was associated with a decreased risk of ER- tumors (per-
allele OR = 0.88; 95% CI = 0.74 to 1.04) but an
increased risk of ER+ tumors (per-allele OR = 1.06; 95%
CI = 0.98 to 1.15; P for heterogeneity = 0.047).
In these analyses, we further confirmed statistically
significant associations with breast cancer risk for 8 of
the 10 candidate SNPs that were identified previously in
published GWAS of breast cancer (most P values were
less than 0.001) (Table 2). We did not observe a statisti-
cally significant association for either LSP1-rs3817198 or
CASP8-rs1045485 (both with P values of 0.13) in our
study, although the direction of the associations was
consistent with that of previous reports [21,22]. We also
calculated, as a positive control, a count GRS based on
these 10 SNPs. We found that each score point increase,
corresponding to one-risk-allele increase, was signifi-
cantly associated with an OR of 1.13 (95% CI = 1.11 to
1.15) for breast cancer (Table 3). Compared with
women in the lowest quintile, women in the highest
quintile had an OR for breast cancer of 1.89 (95% CI =
1.67 to 2.14). For this GRS, the trend in log odds was
significantly steeper for ER+ than for ER- tumors (P for
heterogeneity < 0.001), and the OR across quintiles was
no longer monotonic in ER- tumors (Figure 2).
Discussion
In this large meta-analysis of six population-based stu-
dies, we investigated whether 19 loci linked with age at
menarche and 17 loci linked with age at natural meno-
pause were associated with breast cancer risk among up
to 3,683 breast cancer cases and 34,174 controls. We
found that two SNPs with reported associations with
age at menarche and one SNP with a reported associa-
tion with age at natural menopause were significantly
associated with breast cancer risk. However, no statisti-
cally significant associations were found for GRSs that
combined all 19 or 17 loci associated with each trait,
although the association for age-at-menarche GRS was
marginally statistically significant. We confirmed most
of the candidate loci for breast cancer which were iden-
tified in previous GWAS. Some of these associations
appeared to differ by tumor subtypes defined by ER
status.
In our analyses, most of the candidate SNPs, including
the strongest GWAS hit for age at menarche or age at
natural menopause, were not found to be associated
with breast cancer risk. This is not necessarily surprising
given that age at menarche and age at natural meno-
pause are relatively weak risk factors [2,3], and all candi-
date SNPs collectively explain only a small portion of
the variation of each trait [10,11]. However, two candi-
date SNPs for age at menarche, rs1079866 and
rs7821178, and one candidate SNP for age at natural
menopause, rs2517388, were found to be associated
with breast cancer risk. These associations were not
attenuated after we further adjusted for self-reported
age at menarche and age at natural menopause, suggest-
ing these three genetic loci were associated with breast
cancer risk independently of their associations with age
at menarche or age at natural menopause. It is possible
that these genetic loci have pleiotropic effects on repro-
ductive timing as well as other biological processes lead-
ing to breast cancer, and the observed associations
might be due largely to other biological consequences of
these risk variants that do not manifest themselves as
changes in age at menarche or age at natural meno-
pause. Alternatively, it is also possible that the relatively
crude assignment of these reproductive events to a sin-
gle chronological year is not sufficiently accurate to cap-
ture the biological effect of these processes on breast
cancer risk and the genetic variants contribute indepen-
dent information on the underlying biological risk. The
three candidate SNPs also contributed to breast cancer
risk independently of the known susceptibility loci for
breast cancer, as further adjustment for breast cancer
loci did not materially alter the results.
We found statistically significant evidence of associa-
tion with breast cancer for eight of the 10 breast cancer
susceptibility loci examined: FGFR2-rs2981582, TNRC9-
rs3803662, 1p-rs11249433, 5p-rs7716600, 2q35-
rs13387042, MAP3K1-rs889312, 8q24-rs13281615, and
RAD51L1- rs999737. The direction and magnitude of
these associations were consistent with those of previous
reports [17,18,22-25]. We did not observe a statistically
significant association for either LSP1-rs3817198 or
CASP8-rs1045485. However, these two SNPs had rela-
tively small reported effects that our study might not
have been able to detect. When the 10 candidate SNPs
were combined by using a polygenic risk score, the rela-
tive risk for women in the highest quintile was about
twice that in the lowest quintile, and this is in accor-
dance with other published results [19,26]. In this study,
none of the 10 breast cancer susceptibility loci was sig-
nificantly associated with age at menarche or age at nat-
ural menopause, and this is in line with a previous
report [27].
Given that most of the candidate loci for age at
menarche and age at natural menopause were not asso-
ciated with breast cancer risk, it is not surprising that
there were no statistically significant associations for the
polygenetic risk scores that combined all candidate loci
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for each trait. To conduct a post hoc and exploratory
analysis, we created a polygenetic risk score by including
only the three candidate loci associated with either age
at menarche or age at natural menopause and with
breast cancer risk and found that each risk allele incre-
ment was associated with an approximately 17%
increased risk for breast cancer. Women with four or
more risk alleles had an approximately 60% increased
risk for breast cancer in comparison with those with
two risk alleles or less. When we further combined the
three associated SNPs with the 10 breast cancer suscept-
ibility loci to create a polygenetic risk score, each risk
allele increment was associated with an approximately
18% increased risk for breast cancer. For women with
14 or more risk alleles (the highest quintile), the risk for
breast cancer increased threefold in comparison with
those with 10 or less (the lowest quintile). Because the
former group constitutes approximately 20% of the
study population, the GRS that combines the three can-
didate SNPs for age at menarche and age at natural
menopause and the identified breast cancer susceptibil-
ity loci might be useful for identifying a subgroup of
women with a high genetic risk for breast cancer.
Further research is needed to confirm this finding.
It has been hypothesized that the risk of ER+ breast
cancer is positively associated with a woman’s cumula-
tive lifetime exposure to endogenous ovarian hormones
[28]. A younger age at menarche [12,15,29] and an older
age at menopause [30] have been observed to be more
consistently associated with ER+ than ER- tumors. In
this report, we found that candidate loci for age at
menarche and age at natural menopause may also be
differentially associated with tumor subtypes defined by
ER status. Of the three candidate loci that were found
to be associated with overall breast cancer risk,
rs1079866 was more strongly associated with ER+
tumors, rs7821178 was equally associated with both,
whereas rs2517388 was more strongly associated with
ER- tumors, although differences were not statistically
significant. Importantly, two candidate loci for age at
menarche, rs17188434 and rs17268785, had significantly
different associations with ER+ and ER- tumors.
Whereas both SNPs were not significantly associated
with overall and ER+ breast cancer, the former showed a
statistically significant positive association with ER-
tumors, whereas the latter showed a statistically signifi-
cant inverse association with ER- tumor. These findings
provide further support for the notion that ER+ and ER-
tumors are the result of different etiologic pathways
[31].
Although common genetic variants that influence the
intermediate phenotypes or risk factors have been
hypothesized to subsequently affect disease risk, few stu-
dies have assessed the association between these genetic
variants and disease risk or, furthermore, whether these
associations are mediated through the intermediate phe-
notypes. Chen and colleagues [32] investigated obesity-
linked genetic variants in relation to breast cancer risk
but found no statistically significant association. To our
knowledge, ours is the first study to evaluate the asso-
ciations of candidate loci for age at menarche and age at
natural menopause with breast cancer risk. One of the
strengths of our study is the relatively large combined
sample size achieved through international collabora-
tion. We had adequate statistical power (80%) to detect
an OR of 1.12 for SNPs with a minor allele frequency
(MAF) of 0.10 and an OR of 1.09 for SNPs with an
MAF of 0.20. However, our analysis of ER+ tumors was
less adequately powered, as the ER status was not avail-
able for all cases, and the study had limited statistical
power for ER- tumors. One limitation in our study is
the multiple comparisons that could lead to false-posi-
tive results. Although none of the candidate SNPs with
a reported association with age at menarche or age at
natural menopause survived Bonferroni correction in
the test of breast cancer association, this correction is
considered to be overly conservative given that the can-
didates were chosen on the basis of promising hypoth-
eses. Another potential limitation of our study comes
from differences in the study population and designs
and methods of collecting risk factors and genetic mar-
ker data across studies. However, the findings were gen-
erally consistent across studies, arguing for the
robustness of our results. Finally, as our analyses were
restricted to women of European ancestry, results from
this study may not be generalizable to other ethnic
groups.
Conclusions
In summary, in this large analysis of the association of
several novel candidate loci for age at menarche and age
at natural menopause with breast cancer risk, we
observed that three loci - two for age at menarche and
one for age at natural menopause - were significantly
associated with breast cancer risk independently of their
associations with each trait and independently of known
breast cancer susceptibility loci. These associations may
differ by tumor subtypes defined by ER status. A combi-
nation of all 19 loci associated with age at menarche or
17 loci associated with age at natural menopause did
not appear to be helpful for identifying a high-risk sub-
group for breast cancer.
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Additional file 2: Table S1: Information on the 46 candidate SNP
loci identified in previous genome-wide association studies for age
at menarche, age at natural menopause and breast cancer.
Additional file 3: Table S2: Characteristics of non-genetic risk
factors for breast cancer in each participating study.
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